Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant Candida parapsilosis bloodstream infections
Open Access
- 5 November 2025
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (11) , e0035525
Abstract
Current therapeutic options for fluconazole-resistant Candida parapsilosis (FLZR-CP) bloodstream infections (BSI) are limited to echinocandins and liposomal amphotericin B (L-AmB). To the best of our knowledge, no real-world comparative effectiveness studies have assessed these agents. This study aimed to compare the effectiveness of echinocandins and L-AmB for the treatment of FLZR-CP BSI. This retrospective, observational study was conducted in two hospitals in Italy between January 2018 and December 2022. Eligible patients were adults (≥18 years old) with microbiologically confirmed FLZR-CP BSI who received targeted therapy with either echinocandins or L-AmB. Patients were matched (2:1) based on age, Charlson comorbidity index, presence of sepsis or septic shock, time to appropriate antifungal therapy (≤48 hours or > 48 hours from diagnosis), and infection source. A total of 63 patients were included (42 in the echinocandin group and 21 in the L-AmB group). In Cox regression, targeted therapy with echinocandins was not associated with increased mortality (adjusted hazard ratio 1.40; 95% confidence interval [CI] 0.33–5.92, P = 0.645). An exploratory sensitivity analysis including patients who did not receive source control yielded consistent results ( P = 0.491). Furthermore, in the multivariable regression analysis, echinocandin therapy was not associated with an increased risk of persistent fungemia (adjusted odds ratio 1.61: 95% CI 0.43–5.99, P = 0.476). Treatment with echinocandins and L-AmB resulted in similar 30-day mortality and persistent fungemia rates in patients with FLZR-CP BSI. These findings confirm that echinocandins are a viable treatment option for C. parapsilosis BSI, even for patients with fluconazole-resistant strains.Keywords
This publication has 37 references indexed in Scilit:
- Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort studyThe Lancet Infectious Diseases, 2023
- Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASMThe Lancet Infectious Diseases, 2021
- Resistance to Antifungal DrugsInfectious Disease Clinics of North America, 2021
- Efficacy of a “Checklist” Intervention Bundle on the Clinical Outcome of Patients with Candida Bloodstream Infections: A Quasi-Experimental Pre-Post StudyInfectious Diseases and Therapy, 2020
- Persistent Candidemia in adults: underlying causes and clinical significance in the antifungal stewardship eraEuropean Journal of Clinical Microbiology & Infectious Diseases, 2019
- Risk factors for late recurrent candidaemia. A retrospective matched case–control studyClinical Microbiology and Infection, 2016
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialThe Lancet, 2007
- Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trialThe Lancet, 2005
- Global Distribution and Outcomes for Candida Species Causing Invasive Candidiasis: Results from an International Randomized Double-Blind Study of Caspofungin Versus Amphotericin B for the Treatment of Invasive CandidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003